All In Biotech

Drug Trial Radar · NCT03037385

Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors

A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: May 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

590

Actual

Start

Mar 17, 2017

Primary completion

Mar 21, 2024

Study completion Mar 21, 2024

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Jan 31, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic activity of pralsetinib (BLU-667) administered orally in participants with medullary thyroid cancer (MTC), RET-altered NSCLC and other RET-altered solid tumors.

Conditions

  • RET-altered Non Small Cell Lung Cancer
  • Medullary Thyroid Cancer
  • RET-altered Papillary Thyroid Cancer
  • RET-altered Colon Cancer
  • RET-altered Solid Tumors
  • Lung Neoplasm
  • Carcinoma, Non-Small-Cell Lung
  • Thyroid Diseases
  • Thyroid Neoplasm
  • Thyroid Cancer, Papillary
  • Carcinoma, Neuroendocrine
  • Respiratory Tract Neoplasms
  • Thoracic Neoplasms
  • Neoplasms by Site
  • Neoplasms
  • Lung Diseases
  • Respiratory Tract Disease
  • Carcinoma, Bronchogenic
  • Bronchial Neoplasms
  • Endocrine System Diseases
  • Endocrine Gland Neoplasm
  • Head and Neck Neoplasms
  • Adenocarcinoma, Papillary
  • Adenocarcinoma
  • Carcinoma
  • Neoplasms, Glandular and Epithelial
  • Neoplasms by Histologic Type
  • Neuroendocrine Tumors
  • Neuroectodermal Tumors
  • Neoplasms, Germ Cell and Embryonal
  • Neoplasms, Nerve Tissue
  • Colonic Neoplasms
  • Colorectal Neoplasms
  • Intestinal Neoplasms
  • Gastrointestinal Neoplasms
  • Digestive System Neoplasm
  • Digestive System Disease
  • Gastrointestinal Disease
  • Colonic Diseases
  • Intestinal Disease

Interventions

  • pralsetinib (BLU-667)Drug

    pralsetinib (BLU-667) is a potent and selective inhibitor of the RET mutations, fusions, and predicted resistant mutants

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1 : Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of PralsetinibTime frame: Up to approximately 30.8 months
  2. Phase 1 and Phase 2: Number of Participants With AEs and Serious AEs (SAEs)Time frame: From Cycle 1 Day 1 up to 30 days after the final dose of study drug (up to approximately 6.7 years)
  3. Phase 2: Overall Response Rate (ORR)Time frame: Up to approximately 79.8 months

Locations

71 sites in 13 countries. Site status is shown where the registry gives one.

  • Mayo Clinic Hospital

    Phoenix, Arizona

  • UC Irvine Medical Center

    Orange, California

  • University of Colorado Anschutz Medical Campus

    Aurora, Colorado

  • Georgetown University Medical Center

    Washington D.C., District of Columbia

  • Mayo Clinic-Jacksonville

    Jacksonville, Florida

  • Sylvester Comprehensive Cancer Center

    Miami, Florida

  • Maryland Oncology Hematology, P.A.

    Columbia, Maryland

  • Massachusetts General Hospital.

    Boston, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • Mayo Clinic Rochester

    Rochester, Minnesota

  • Washington University School of Medicine in St. Louis

    St Louis, Missouri

  • Albany Medical Center

    Albany, New York

  • Weill Cornell Medical College-New York Presbyterian Hospital

    New York, New York

  • Oregon Health & Science University

    Portland, Oregon

  • Texas Oncology-Austin Midtown

    Austin, Texas

  • Texas Oncology - Baylor Charles A. Sammons Cancer Center

    Dallas, Texas

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Seattle Cancer Care Alliance

    Seattle, Washington

  • Antwerp University Hospital

    Edegem, Belgium

  • Beijing Cancer Hospital

    Beijing, China

  • Beijing Cancer Hospital

    Beijing, China

  • The affiliated Cancer Hospital, School of Medicine, UESTC

    Chengdu, China

  • West China Hospital, Sichuan University

    Chengdu, China

  • Chongqing Cancer Hospital

    Chongqing, China

  • Fujian Provincial Cancer Hospital

    Fuzhou, China

  • First Affiliated Hospital of Gannan Medical University

    Ganzhou, China

  • Sun Yet-sen University Cancer Center

    Guangzhou, China

  • Guangdong General Hospital

    Guangzhou, China

  • Zhejiang Cancer Hospital

    Hangzhou, China

  • Jinan Central Hospital

    Jinan, China

  • Gansu Cancer Hospital

    Lanzhou, China

  • Fudan University Shanghai Cancer Center

    Shanghai, China

  • Fudan University Shanghai Cancer Center

    Shanghai, China

  • Tianjin Medical University Cancer Institute & Hospital

    Tianjing, China

  • Union Hospital Tongji Medical College Huazhong University of Science and Technology

    Wuhan, China

  • Henan Cancer Hospital

    Zhengzhou, China

  • Institut Bergonie

    Bordeaux, France

  • Centre Hospitalier Régional Universitaire de Lille (CHRU) - Hôpital Claude Huriez

    Lille, France

  • Centre Léon Bérard

    Lyon, France

  • Centre Antoine Lacassagne

    Nice, France

Showing 40 of 71 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.